Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...
Image: Adobe Stock “Improvements in ... reports of pyrexia (21%), headache (18%), infective pulmonary exacerbation of cystic fibrosis (17%) and oropharyngeal pain (17%). Among those who reported ...
Medical Xpress on MSN14d
Early immune system changes contribute to lung damage in cystic fibrosisDespite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
Cystic fibrosis (CF) is a progressive genetic disease that adversely affects a person's lungs, pancreas and other vital organs, says Dr. Michael Boyle, president and CEO of the Cystic Fibrosis ...
Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.
Chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis (also called idiopathic pulmonary fibrosis, or IPF) are both serious lifelong diseases that make it hard for you to breathe.
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback